Gapping up
In reaction to strong earnings/guidance: HOG +7.5%, NFLX +7.2% (also upgraded to Buy from Hold at Cantor Fitzgerald; upgraded to Outperform from Mkt Perform at Raymond James ), PLXT +6.7%, RCII +4.8%, CE +3.6%, HLX +3.3%, (light volume), CMCSA +2.2%, LMT +2.2%, CYS +1.4%, (light volume), CNC +0.3%, TRV +0.2%.
M&A news: AGN +20.1% and VRX +9.9% (Valeant proposes to combine with allergan for $48.30 in cash and 0.83 shares of Valeant stock for each Allergan Share; Valeant Pharma's Q1 is expected to meet or beat consensus Cash EPS expectations), GSK+4.7% (Novartis AG acquires GSK oncology products), NVS +1.2% (Eli Lilly agrees to acquire Novartis Animal Health; Novartis AG acquires GSK oncology products), PFE +0.5% (Bloomberg discusses that large deals make sense for PFE and AZN), .
Select metals/mining stocks trading higher: ABX +2.4% (upgraded to Buy from Neutral at Goldman), VALE +2.2%, GFI +1.3%, GDX +0.9%.
Select solar related names showing strength: JASO +1.8%, FSLR +1.6% (initiated with a Buy at Brean Capital),CSIQ +1.2% ( to Supply 43MW of Solar Modules in Japan), SPWR +0.8% (initiated with a Buy at Brean Capital).
Other news: SPNC +6.1% (attributed to positive analyst mention on CNBC), MHR +5.7% (Magnum Hunter announces execution of a definitive agreement to sell remaining Canadian assets for CAD75 mln), EJ +5.3% (still checking), IMUC +5% ( announces ICT-107 Phase 2 data abstract accepted for oral presentation at the 2014 ASCO annual meeting), RTK +4.1% (Blackstone Group discloses 16.5% stake in 13D filing), WB +3.9% (continued momentum), RVNC +3.6% (announces positive results from the RT002 Phase 1/2 study in glabellar (frown) lines), GILD +2.2% (Gilead Sciences' New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA), SGMS +1.5% (Scientific Games signed a contract with La Francaise des Jeux, the operator of the French National Lottery), BA +1.3% (Shandong Airlines plans to purchase 50 BA aircraft ), CSCO +1.3% (still checking), DEO +1.2% (still checking), TSLA +0.9% (Tesla Motors and Panasonic likely to partner in battery plant, according to reports ), KORS +0.7% (Lone Pine Capital disclosed 5.5% stake in 13G), MU +0.7% ( following positive Barron's mention), LLY +0.6% (Eli Lilly's Cyramza approved by FDA to treat patients with advanced stomach cancer or gastroesophageal junction adenocarcinoma; Eli Lilly agrees to acquire Novartis Animal Health ).
Analyst comments: TWOU +6.1% (initiated by several analysts), RKUS +2.7% (Ruckus Wireless assumed with an Overweight at Piper Jaffray), GWPH +2.5% (initiated with a Overweight at Morgan Stanley), FB +1.9% (upgraded to Outperform from Neutral at Credit Suisse; tgt raised to $87 from $65), PRGO +1.6% (initiated with a Buy at Jefferies), AKRX +1.5% (initiated with a Buy at Jefferies), DYAX +1.5% (Dyax initiated with a Buy at BofA/Merrill), SHPG +1.2% (initiated with a Buy at Jefferies), IMMR +1.1% (initiated with a Buy at B. Riley & Co), HD +0.9% (upgraded to Outperform from Mkt Perform at BMO Capital Mkt)
M&A news: AGN +20.1% and VRX +9.9% (Valeant proposes to combine with allergan for $48.30 in cash and 0.83 shares of Valeant stock for each Allergan Share; Valeant Pharma's Q1 is expected to meet or beat consensus Cash EPS expectations), GSK+4.7% (Novartis AG acquires GSK oncology products), NVS +1.2% (Eli Lilly agrees to acquire Novartis Animal Health; Novartis AG acquires GSK oncology products), PFE +0.5% (Bloomberg discusses that large deals make sense for PFE and AZN), .
Select metals/mining stocks trading higher: ABX +2.4% (upgraded to Buy from Neutral at Goldman), VALE +2.2%, GFI +1.3%, GDX +0.9%.
Select solar related names showing strength: JASO +1.8%, FSLR +1.6% (initiated with a Buy at Brean Capital),CSIQ +1.2% ( to Supply 43MW of Solar Modules in Japan), SPWR +0.8% (initiated with a Buy at Brean Capital).
Other news: SPNC +6.1% (attributed to positive analyst mention on CNBC), MHR +5.7% (Magnum Hunter announces execution of a definitive agreement to sell remaining Canadian assets for CAD75 mln), EJ +5.3% (still checking), IMUC +5% ( announces ICT-107 Phase 2 data abstract accepted for oral presentation at the 2014 ASCO annual meeting), RTK +4.1% (Blackstone Group discloses 16.5% stake in 13D filing), WB +3.9% (continued momentum), RVNC +3.6% (announces positive results from the RT002 Phase 1/2 study in glabellar (frown) lines), GILD +2.2% (Gilead Sciences' New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA), SGMS +1.5% (Scientific Games signed a contract with La Francaise des Jeux, the operator of the French National Lottery), BA +1.3% (Shandong Airlines plans to purchase 50 BA aircraft ), CSCO +1.3% (still checking), DEO +1.2% (still checking), TSLA +0.9% (Tesla Motors and Panasonic likely to partner in battery plant, according to reports ), KORS +0.7% (Lone Pine Capital disclosed 5.5% stake in 13G), MU +0.7% ( following positive Barron's mention), LLY +0.6% (Eli Lilly's Cyramza approved by FDA to treat patients with advanced stomach cancer or gastroesophageal junction adenocarcinoma; Eli Lilly agrees to acquire Novartis Animal Health ).
Analyst comments: TWOU +6.1% (initiated by several analysts), RKUS +2.7% (Ruckus Wireless assumed with an Overweight at Piper Jaffray), GWPH +2.5% (initiated with a Overweight at Morgan Stanley), FB +1.9% (upgraded to Outperform from Neutral at Credit Suisse; tgt raised to $87 from $65), PRGO +1.6% (initiated with a Buy at Jefferies), AKRX +1.5% (initiated with a Buy at Jefferies), DYAX +1.5% (Dyax initiated with a Buy at BofA/Merrill), SHPG +1.2% (initiated with a Buy at Jefferies), IMMR +1.1% (initiated with a Buy at B. Riley & Co), HD +0.9% (upgraded to Outperform from Mkt Perform at BMO Capital Mkt)